Gene editing: can CRISPR cure ATTR?

28 August 2026 (09:27 - 09:45)

Organised by:

Video

Sign in for access options

Slides

About the speaker

Doctor Julian Gillmore

UCL, Greater London (United Kingdom of Great Britain & Northern Ireland)

4 More presentations in this session

Presentation thumbnail

Why amyloid heart disease became treatable: TTR biology and the therapeutic ladder

Doctor L. Obici (Pavia, IT)

Presentation thumbnail

Diagnosis and the window for cure: imaging, biomarkers, and gene-carrier screening

Doctor E. Gonzalez Lopez (Madrid, ES)

Presentation thumbnail

Silencing TTR: siRNA and antisense in the clinic

Doctor M. Maurer (New York, US)

Presentation thumbnail

Clearing deposited amyloid: antibody-based depletion

Doctor P. Garcia-Pavia (Majadahonda, ES)

Access the full session

Session thumbnail

Frontiers in amyloid heart disease: from treatment to cure

The Event

Event poster

ESC Congress 2026

28 August 2026 09:27 CET

You may be interested in

Congress Presentation

Editing the future: gene therapies transforming cardiomyopathy care

29 August 2026

Congress Presentation

Durable survival benefits of acoramidis over 54 months in variant transthyretin amyloid cardiomyopathy (ATTR-CM), including p.V142I: interim findings from ATTRibute-CM and its open-label extension

30 August 2026

Congress Presentation

CRISPR gene editing with nexiguran ziclumeran in ATTR cardiomyopathy: treatment effect in hereditary vs. wild-type disease

17 May 2025

Congress Presentation

In vivo gene editing with YOLT-201 for transthyretin amyloid cardiomyopathy – an open-label, first-in-human clinical trial

31 August 2026

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources